Akero Therapeutics Announces New Phase 2b Clinical Data for Efruxifermin in MASH at Upcoming AASLD 2025 Liver Meeting
Reuters
Oct 07
Akero Therapeutics Announces New Phase 2b Clinical Data for Efruxifermin in MASH at Upcoming AASLD 2025 Liver Meeting
Akero Therapeutics Inc. has announced upcoming presentations of new data from its Phase 2b SYMMETRY and HARMONY studies evaluating efruxifermin $(EFX)$, the company's lead product candidate, at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, scheduled for November 7-11, 2025, in Washington, DC. The presentations will include findings from the 96-week SYMMETRY study assessing the safety and efficacy of efruxifermin in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH), as well as results from an AI-powered digital analysis of histology data from the 96-week HARMONY study in patients with pre-cirrhotic (F2-F3) MASH. The results from these studies will be presented at the conference and have not yet been publicly disclosed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541115-en) on October 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.